Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-06-23
2011-12-06
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S066000
Reexamination Certificate
active
08071590
ABSTRACT:
A subject of the invention is the compounds of formula (I):wherein R1, R2, R3, R′3, R4, R′4, R5, R6and R7are as described in the application,in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.
REFERENCES:
patent: 4649144 (1987-03-01), Matsumoto et al.
patent: 4801584 (1989-01-01), Yokose et al.
patent: 4990517 (1991-02-01), Petersen et al.
patent: 5354747 (1994-10-01), Hansen et al.
patent: 5480879 (1996-01-01), Petersen et al.
patent: 5508278 (1996-04-01), Jaetsch et al.
patent: 5576314 (1996-11-01), Power et al.
patent: 5679675 (1997-10-01), Jaetsch et al.
patent: 6284757 (2001-09-01), Sanner
patent: 2003/0225107 (2003-12-01), Fukuda
patent: 2004/0110810 (2004-06-01), Ciufolini et al.
patent: 2005/0239852 (2005-10-01), Ciufolini et al.
patent: 2007/0142390 (2007-06-01), Moussy et al.
patent: 2008/0039466 (2008-02-01), Moussy et al.
patent: 2008/0255141 (2008-10-01), Ciufolini et al.
patent: 2009/0221565 (2009-09-01), Ropp et al.
patent: 0 259 804 (1988-03-01), None
patent: 0 394 553 (1989-03-01), None
patent: 0 343 524 (1989-11-01), None
patent: 0 470 252 (1990-04-01), None
patent: 0 647 644 (1994-08-01), None
patent: 0 682 030 (1995-04-01), None
patent: 0 688 772 (1995-06-01), None
patent: 1 182 202 (2002-02-01), None
patent: WO 97/27201 (1997-07-01), None
patent: WO 2004/005295 (2004-01-01), None
patent: WO 2004/096221 (2004-11-01), None
patent: WO 2005/026154 (2005-03-01), None
patent: WO 2006/027694 (2005-08-01), None
patent: WO 2006/072831 (2005-12-01), None
patent: WO 2006/044454 (2006-04-01), None
patent: WO 2007/011284 (2007-01-01), None
patent: WO 2007/021982 (2007-02-01), None
patent: WO 2007/085760 (2007-02-01), None
patent: WO 2007/028654 (2007-03-01), None
Cain, James P. et al., “Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the menaocortin receptors,” Bioorganic & Medicinal Chemistry Letters 16 (2006) pp. 5462-5467.
Cesare, P. Di. et al., “Fluoronaphthyridines and -quinolones as Antibacterial Agents. 5. Synthesis and Antimicrobial Actiivty of Chiral 1-tert-Butyl-6-fluoro-7-substituted-naphthyridones;” J. Med. Chem. 1992, vol. 35, pp. 4205-4213.
Dax, S.L. et al.: “Quinolone Antibacterials: A Hydroxymethylation—Intramolecular Cyclization Route To Pyrido [3,2,1-ij]-1,3,4-Benzoxadiazines;” J. Org. Chem., vol. 57, No. 2, 1992; pp. 744-746.
Falorni, Massimo et al., “Chiral Ligands Containing Heteroatoms. 15.1 Cyclic β-Amino Alcohols as Chiral Inductors for Enantioselective Reductions of Ketones,” Tetrahedron: Asymmetry, vol. 7, No. 9, 1996, pp. 2739-2742.
Falorni, Massimo et al., “Chiral Ligands Containing Heteroatoms. 11.1 Optically Active 2-Hydroxymethyl Piperazines as Catalysts in the Enantioselective Addition of Diethylzinc to Benzaidehyde,” Tetrahedron: Asymmetry, vol. 4, No. 11, 1993, pp. 2389-2398.
Falorni, Massimo et al., “Synthesis of (2R,5S)- and (2S,5S)-2-Carboxy-1,4-diaza-[4.3.0]bicyclononane as Building Blocks for the Synthesis of New Potential HIV Protease Inhibitors,” Tetrahedron: Asymmetry, vol. 7, No. 7, 1996, pp. 1999-2005.
Jain, Sanjay et al., Lactam & Amide Acetals XXI. Use of Pyroglutamic Acid and Proline in Chiral Synthesis of Conformationally Constrained Piperazinones, Tetrahedron vol. 48, No. 23, 1992, pp. 4985-4998.
Li, Qun et al., “Synthesis and Structure—Activity Relationships of 2-Pyridones: A Novel Series of Potent DNA Gyrase Inhibitors as Antibacterial Agents;” J. Med. Chem. 1996, vol. 39, pp. 3070-3088.
Peng, Hairuo et al., “Novel Bicyclic Piperazine Derivatives of Triazolotriazine and Triazolopyrimidines as Highly Potent and Selective Adenosine A2A Receptor Antagonists,” J. Med. Chem. 2004, 47, Oct. 30, 2004, pp. 6218-6229.
Poumarat, F. et al.; “Mise Au Point Et Evaluation D'Une Methode Opacimetrique Pour La Determination De L'Antibiosensibilite De Mycoplasma Bovis In Vitro;” Ann, Rech. Vet. (20), 1989; pp. 135-143.
Scapecchi, Serena et al., “Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs,” Bioorganic & Medicinal Chemistry 12 (2004), pp. 71-85.
Snyder et al., PubMed Abstract (J. Med. Liban 48(4): 208-214, Jul.-Aug. 2000.
Tomita, Kyoji et al., “Synthesis and Structure—Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1,” J. Med. Chem. 2002, vol. 45, pp. 5564-5575.
Tsuzuki, Yasunori et al., “Synthesis and Structure—Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyI)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 2,” J. Med. Chem. 2004, vol. 47, pp. 2097-2109.
Chery-Mozziconacci Florence
Ciapetti Paola
Giethlen Bruno
Leblanc Francoise
Morice Christophe
Habte Kahsay T
Harness & Dickey & Pierce P.L.C.
Vetoquinol SA
LandOfFree
9-substituted-5-carboxy-oxadiazino-quinolone derivatives,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 9-substituted-5-carboxy-oxadiazino-quinolone derivatives,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 9-substituted-5-carboxy-oxadiazino-quinolone derivatives,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270377